Method for the synthesis of 2,4-dimethylpyrimidin-5-ol, intermediates, and method for the synthesis of Lemborexant using the intermediates
US 11,891,375 In forceTerm ends Jul 25, 2042 · From the USPTO record
20-year base term ends Jul 25, 2042
Jul 25, 2022
Jul 25, 2042
Feb 6, 2024
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jul 25, 2022, when this application, 17/814,815, was filed | Jul 25, 2042 | From the USPTO record |
| Continuity chain | Every parent in the chain resolved | no change | From the USPTO record |
| Patent term adjustment | No term adjustment record on a grant after 2005, so none is added | no change | From the USPTO record |
| Terminal disclaimer cap | None on record | no cap applied | From the USPTO record |
| Patent term extension | None on file | no change | From the USPTO record |
| Fee events | 0 of 3 maintenance fees paid | In force | From the USPTO record |
| Computed term end | The steps above, in order | Jul 25, 2042 | From the USPTO record |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Not on this page: the patent's family, its recorded assignments and its citation count. USPTO's assignment records, linked above, list every recorded assignment.
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.